Platinum (P) doublet with either Pemetrexed (Alimta, A) or Docetaxel (D) is considered as a standard first line regimen for NSq-NSCLC. D is being used in 60 mg/m2 3 weekly dosage in Japan and several east Asian countries instead of 75 mg/m2 3 weekly dose of western countries. In this prospective randomized trial, we are recruiting patients with chemo naïve stage IV NSq-NSCLC to compare DP 60 and 70 mg/m3 3 weekly regimen and AP 500 and 70 mg/m2 3 weekly regimen. To prove non-inferiority of progression free survival of DP compared to AP, 276 patients will be enrolled to this trial. Since August 2011, 72 patients (48 male, 24 female, mean age 62.6 years) were enrolled to this trial. Patients were randomized into AP group (n=37) or DP group (n=35). Number of cycles and dose reduction rate are not different in both groups, respectively (AP: 2.7 cycles, 18.2% vs. DP: 2.4 cycles, 22.6%, p＞0.05). Similar response rate are being observed in both groups (AP: 7/37 (18.9%) vs. DP: 7/35 (20.0%)). In this interim analysis both AP and DP regimens are well tolerated, and show similar efficacy. Active recruitment should be followed to prove significant clinical evidence (ClinicalTrials.gov Identifier: NCT01282151).